Loading...
•
Dec 31, 2022
Celldex Q4 2022 Earnings Report
Reported financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update.
Key Takeaways
Celldex reported a net loss of $26.5 million, or ($0.56) per share, for the fourth quarter of 2022. Total revenue was $1.6 million, and research and development expenses were $22.9 million. Cash, cash equivalents, and marketable securities totaled $305.0 million as of December 31, 2022.
Phase 1b multi-dose CSU data presented at AAAAI on February 26.
Phase 2 CSU enrollment completion expected by Q3 2023.
Rita Jain, M.D. appointed to the Company’s Board of Directors.
Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2022 are sufficient to meet estimated working capital requirements and fund planned operations through 2025.
Celldex
Celldex
Forward Guidance
Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2022 are sufficient to meet estimated working capital requirements and fund planned operations through 2025, which include their ongoing Phase 1b studies in urticaria and prurigo nodularis and their ongoing and planned Phase 2 studies in CSU, CIndU and EoE.